Company: GRCE
Filing Date: 2025-03-10
Form Type: S-3
Source: 0001140361-25-007769
Chunk: 2

Company: Grace Therapeutics, Inc.
Filing Date: 2025-03-10
Form: S-3
Chunk 2
---
 “Selling Stockholders”), of up to 8,836,584 shares of our common stock, par value $0.0001 (the “Common Stock”), which are comprised of (i) 3,276,874
          shares of Common Stock (the “Shares”) and (ii) 5,559,710‬ shares of Common Stock (the “Warrant Shares”) issuable upon the exercise of either pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) or common warrants to
          purchase shares of Common Stock (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”).

We are registering the offer and resale of the Shares and Warrant Shares to
          satisfy the provisions of that certain Registration Rights Agreement, by and between us and the investors party thereto, dated as of February 10, 2025 (the “Registration Rights Agreement”), in connection with our private placement of securities,
          which closed on February 11, 2025 (the “Private Placement Offering”), pursuant to those two certain Securities Purchase Agreements, by and between us and the investors party thereto, each dated as of February 10, 2025 (the “Securities Purchase
          Agreements”).

We are not selling any shares of Common Stock under this prospectus and will not
          receive any of the proceeds from the sale of the Shares and Warrant Shares by the Selling Stockholders. We will, however, receive the net proceeds of any Warrants exercised for cash.

The Selling Stockholders may sell or otherwise dispose of the Common Stock
          covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Stockholders may sell or otherwise dispose of the Common Stock covered by this prospectus in the section entitled
          “Plan of Distribution” on page 9 . Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Common Stock covered by this prospectus will be borne by the Selling Stockholders. We will pay
          all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of the Common Stock covered by this prospectus.

Our Common Stock is traded on The Nasdaq Capital Market under the symbol “GRCE.”
          On March 7, 2025, the last reported sale price of our Common Stock on The Nasdaq Capital Market was $2.54 per share.

INVEST